Elanco Animal Health (ELAN) Tops Q3 EPS by 4c, Revenues Miss; Offers FY18 EPS Outlook Above Consensus,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Elanco Animal Health (ELAN) Announces Collaboration Agreement with Novozymes
November 2, 2018 6:53 AM EDTElanco Animal Health Incorporated (NYSE: ELAN), announced today a new global R&D collaboration with Novozymes A/S (OMX: NZYM B), the world leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally.
The effort will leverage Novozymes leading discovery and development programs, and together the companies will collaborate to develop a R&D pipeline and commercialize products in the next decade.
Nutritional health is an exciting platform that will define the next generation of feed additives to improve... More
